Becton Dickinson vs Grok

Side-by-side comparison of AI visibility scores, market position, and capabilities

Becton Dickinson leads in AI visibility (69 vs 49)
Becton Dickinson logo

Becton Dickinson

LeaderHealthcare Tech

Enterprise

Franklin Lakes NJ medical technology (NYSE: BDX) at $21.8B FY2025 revenue (+8.2%); $17.5B Reverse Morris Trust spinoff with Waters (2025), Edwards critical care acquisition $4.2B (2024) competing with Baxter for infusion systems.

AI VisibilityBeta
Overall Score
B69
Category Rank
#120 of 290
AI Consensus
71%
Trend
stable
Per Platform
ChatGPT
73
Perplexity
76
Gemini
63

About

Becton, Dickinson and Company (BD) is a Franklin Lakes, New Jersey-based global medical technology company — publicly traded on the New York Stock Exchange (NYSE: BDX) as an S&P 500 Health Care component — manufacturing and selling medical supplies, devices, laboratory equipment, and diagnostic products through approximately 74,000 employees serving healthcare institutions, clinical laboratories, pharmaceutical companies, and life science researchers in over 190 countries. In fiscal year 2025 (ended September 30, 2025), BD reported full-year revenue of $21.8 billion (up 8.2% year-over-year) with Q4 FY2025 revenue of $5.9 billion (+8.3% reported, +3.9% organic growth), and declared a quarterly dividend of $1.05 per share (+1%). Founded in 1897 in New York City by Maxwell Becton and Fairleigh Dickinson Sr. as a thermometer and surgical instrument maker, BD has grown through 125+ years of acquisitions to become a Fortune 500 ($21.8B revenue, #211 on 2024 Fortune 500) global medtech leader. The company operates through three segments: BD Medical (~50% of revenue, IV catheters, syringes, prefillable drug delivery systems, and medication management solutions), BD Life Sciences (flow cytometry, microbiology, molecular diagnostics, and lab automation), and BD Interventional (advanced patient monitoring, interventional cardiology, and peripheral vascular interventions). BD invests $1.2+ billion annually in R&D. In 2024, BD acquired Edwards Lifesciences' critical care monitoring unit for $4.2 billion.

Full profile
Grok logo

Grok

ChallengerAI & Machine Learning

AI Assistant

AI assistant by xAI (Elon Musk); Grok 3 topped reasoning benchmarks in Feb 2025; 1M+ paying subscribers in week one; real-time X post access; distributed via X Premium; xAI valued at $24B.

AI VisibilityBeta
Overall Score
C49
Category Rank
#4 of 4
AI Consensus
59%
Trend
up
Per Platform
ChatGPT
43
Perplexity
49
Gemini
51

About

Grok is the AI assistant developed by xAI, Elon Musk's AI company founded in 2023, and distributed primarily through X (formerly Twitter). Grok launched in November 2023 as an X Premium perk, with the notable differentiator of real-time access to X posts and a less restricted, more direct conversational style. Grok 3, released in February 2025, achieved top scores on the AIME math reasoning benchmark and ARC-AGI test, briefly positioning xAI as a frontier model lab.

Full profile

AI Visibility Head-to-Head

69
Overall Score
49
#120
Category Rank
#4
71
AI Consensus
59
stable
Trend
up
73
ChatGPT
43
76
Perplexity
49
63
Gemini
51
70
Claude
42
70
Grok
59

Key Details

Category
Enterprise
AI Assistant
Tier
Leader
Challenger
Entity Type
company
product

Capabilities & Ecosystem

Capabilities

Only Grok
AI Assistant

Integrations

Only Becton Dickinson
Becton Dickinson is classified as company. Grok is classified as product (part of xAI).

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.